Naveen Pemmaraju

New Capabilities

Chief of Myeloid Malignancies, MD Anderson Cancer Center

The FDA approved AbbVie's Decnupaz on May 27 for blastic plasmacytoid dendritic cell neoplasm, an aggressive blood cancer that strikes an estimated few hundred Americans a year. It is the second drug ever cleared for the disease and the first that doctors can start in an outpatient clinic instead of a hospital admission.

Updated Yesterday